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Gastrointestinal neuroendocrine neoplasms (GI-NENs) arise from neuroendocrine cells
distributed mainly in the mucosa and submucosa of the gastrointestinal tract. In 2010,
the World Health Organization (WHO) classification of NENs of the digestive system was
changed, categorizing these tumors as grade 1 neuroendocrine tumor (NET), grade-2NET,
neuroendocrine carcinoma (large- or small-cell type), or mixed adenoneuroendocrine
carcinoma (MANEC). Such a classification is based on the Ki-67 index and mitotic count
in histological material. For the accurate pathological diagnosis and grading of NENs, it is
important to clearly recognize the characteristic histological features of GI-NENs and to
understand the correct method of counting Ki-67 and mitoses. In this review, we focus
on the histopathological features of GI-NENs, particularly regarding biopsy and cytological
diagnoses, neuroendocrine markers, genetic and molecular features, and the evaluation of
the Ki-67 index and mitotic count. In addition, we will address the histological features of
GI-NEN in specific organs.
Keywords: neuroendocrine neoplasm, carcinoid, neuroendocrine carcinoma, gastrointestinal tract, neuroendocrine
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INTRODUCTION
Gastrointestinal neuroendocrine neoplasms (GI-NENs) arise
from neuroendocrine cells distributed mainly in the mucosa and
submucosa of the gastrointestinal tract. Although multiple diag-
nostic tools, such as computed tomography, magnetic resonance
imaging, ultrasonography, serological tests, and endoscopy, have
been developed, pathological investigation is needed for diagno-
sis of GI-NENs. In 2010, the World Health Organization (WHO)
announced a new classification system for NENs of the digestive
tract to categorize these tumors as neuroendocrine tumor (NET)
Grade (G) 1 (G1-NET), G2-NET, neuroendocrine carcinoma
(NEC) large- or small-cell type, andmixed adenoneuroendocrine
carcinoma (MANEC) (Bosman et al., 2010). This classification is
made using Ki-67 index and mitotic count in histological mate-
rial. Here, we mainly discuss the histopathological features of
GI-NEN, including grading and staging, biopsy and cytological
diagnoses, neuroendocrine markers, genetic and molecular fea-
tures, and the evaluation of the Ki-67 index and mitotic count.
In addition, we address the histological features of GI-NEN in
specific organs.
GENERAL HISTOPATHOLOGICAL FEATURES OF GI-NENs
Although the histological features of each GI-NEN depend on
the anatomical site and endocrine cell origin, characteristic
histopathological features of GI-NENs are generally held in com-
mon. Macroscopically, NETs are whitish to yellowish or grayish
solid tumors with a nodular or polypoid appearance (Figure 1).
The overlying mucosa is generally intact or shows slight focal
ulceration because the main lesions of G1- and G2-NETs are deep
in the mucosa and submucosa. In contrast, NECs (G3-NETs)
are generally larger and occasionally show ulcerated masses as
in conventional carcinomas (Figure 2). Microscopically, G1- and
G2-NETs are composed of tumor cells possessing round or oval
nuclei with “salt and pepper” chromatin and eosinophilic granu-
lar cytoplasm. The tumor nests are arranged in trabecular, insular,
or sheet-like patterns. NECs are classified as small- or large-cell
carcinomas (Bosman et al., 2010). The basic histological fea-
tures of small- and large-cell carcinomas of the gastrointestinal
tract are similar to those of the lung or other organs (Kajiwara
et al., 2009; Bosman et al., 2010). Small-cell carcinomas con-
sist of small, round, ovoid or spindle-shaped tumor cells with
scant cytoplasm; they are mainly arranged in a sheet-like pattern.
Nuclei of small-cell carcinomas show fine granular chromatin
with absent or inconspicuous nucleoli. Large-cell carcinomas are
composed of medium- or large-sized tumor cells possessing large
atypical nuclei with evident nucleoli. The nuclear to cytoplas-
mic ratio of large-cell carcinomas is lower than that of small-cell
carcinomas (Kajiwara et al., 2009; Stojsic et al., 2010). MANECs
are malignant tumors composed of both adenocarcinoma and
neuroendocrine carcinoma components, with each component
accounting for more than 30% of the tumor (Bosman et al.,
2010). Squamous cell carcinomas coexisting with NECs have also
been reported in the esophagus and duodenum (Yamamoto et al.,
2003; Nassar et al., 2005).
www.frontiersin.org January 2013 | Volume 3 | Article 2 | 1
Hirabayashi et al. Review of GI-NENs
FIGURE 1 | Rectal neuroendocrine tumor (NET): a solitary sessile mass
with slight ulceration.
FIGURE 2 | Neuroendocrine carcinoma (NEC) at the esophagogastric
junction: a large ulcerated mass.
GRADING AND STAGING OF GI-NENs
In 2010, theWHO launched a new classification system for NENs
of the digestive tract, which categorizes them as follows: NET G1,
NET G2, NEC (large- or small-cell type), and MANEC (Bosman
et al., 2010). NET can be equated with carcinoid (Bosman et al.,
2010). “G3-NET” has been used as the category for NEC but
is not advised, since NETs are by definition well-differentiated
(Bosman et al., 2010). This current WHO classification classi-
fies NENs based only on the Ki-67 index and the evaluation
of mitoses in histological material. This classification system is
based on the grading system formerly proposed by the European
Neuroendocrine Tumor Society (ENETS) (Rindi et al., 2006,
2007). According to the current WHO and ENETS grading sys-
tems, G1-NET is designated by a mitotic count of <2 per 2mm2
(10 high power fields [HPF], 40× magnification) and/or ≤2%
Ki-67 index; G2-NET by a mitotic count of 2–20 per 2mm2
and/or 3–20% Ki-67 index; G3-NET by mitotic count of >20
per 2mm2 and/or >20% Ki-67 index (Rindi et al., 2006, 2007;
Bosman et al., 2010). The survival analysis for foregut NENs (gas-
tric, duodenal, or pancreatic), according to the ENETS-WHO
2010 grading system, showed that survival for patients who had
G3 tumors was significantly poorer than that for patients who had
G1 andG2 tumors (G1 vs. G3 andG2 vs. G3, P < 0.01). Similarly,
survival for patients who had G2 tumors was significantly poorer
than that for patients who had G1 tumors (G1 vs. G2, P = 0.04)
(Pape et al., 2008). La Rosa et al. proposed a new global histologic
grading system that combined the histologic patterns, based on
the WHO 2000 classification, and the ENETS-WHO 2010 pro-
liferative grading system. This global grading system improved
tumor prognostic stratification (P < 0.001; global grade 1 vs.
global grade 2, P = 0.007; global grade 1 vs. global grade 3,
P < 0.001; global grade 2 vs. global grade 3, P = 0.001) (La Rosa
et al., 2011). The WHO classification requires scanning of at least
50 fields (at 40× magnification) in the areas with the highest
mitotic density for the evaluation of the mitotic index in 10 HPF,
while ENETS requires at least 40 fields (Rindi et al., 2006, 2007;
Bosman et al., 2010). According to the ENETS grading system, 10
HPF corresponds to 2mm2 (Rindi et al., 2006, 2007). However,
the size of the HPF differs according to the field number of the
eyepiece of each microscope. In breast carcinoma, the adjust-
ment criteria for mitotic count according to the field number
of each microscope eyepiece have been proposed (Tsuda et al.,
2000). To our knowledge, adjustment criteria for mitotic count
according to eyepiece field number for NENs have not been pro-
posed. Accurate grading of NENs might require the development
of adjustment criteria for determining mitotic count. The Ki-67
index is calculated as the percentage of Ki-67–positive tumor cells
in the areas of the highest density of Ki-67–positive cells, oth-
erwise known as “hot spots.” To evaluate the Ki-67 index, the
WHO classification requires 500–2000 tumor cells, while ENETS
requires 2000 tumor cells (Rindi et al., 2006, 2007; Bosman et al.,
2010). Careful selection of hot spots is crucial for accurate eval-
uation of the Ki-67 index. In some cases, Ki-67 staining on
different and multiple slices could be useful for accurate Ki-67
index evaluation.
So far, two different TNM classifications have been proposed
by ENETS and the Union for International Cancer Control
(UICC) (Rindi et al., 2006, 2007; Sobin et al., 2009). There are
some differences between these staging systems. ENETS stag-
ing system applies to all grades of NENs (Rindi et al., 2006,
2007). In contrast, in the seventh edition of the UICC staging
system, GI-carcinoid (ENTES G1 and G2) has a specific staging
depending on the site of origin, whereas large-cell and small-cell
carcinoma (GI-NEC) and all pancreatic NENs are staged like con-
ventional carcinoma (Sobin et al., 2009). Consequently, in the
case of pancreatic NENs, a discrepancy in the T-stage (primary
tumor stage) between ENETS and UICC staging systems has
been observed in 18% cases (Liszka et al., 2011). In the case of
GI-NENs, the definitions of T-stage for appendiceal and gastric
NENs differ between the two staging systems (see Tables 1 and 2)
(Rindi et al., 2006, 2007; Sobin et al., 2009). These differences
between ENETS and UICC staging systems may cause confusion
in practice and research. Therefore, it is critical to clarify which
classification system is being used or document the pathological
features, such as tumor size and invasion, that allow for the trans-
lation of T-stage between ENETS and UICC classification (Rindi
et al., 2006; Kloppel et al., 2010).
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Table 1 | Comparison of T stage of gastric NENs between ENETS and
UICC.
ENETS UICC
Tis In situ tumor/dysplasia (<0.5mm) Mucosa 0.5mm
T1 Tumor invades lamina propria or
submucosa and ≤1 cm
Mucosa 0.5–1 cm or
submucosa ≤1cm
T2 Tumor invades muscularis propria
or subserosa or >1 cm
Muscularis propria or >1 cm
T3 Tumor penetrates serosa Subserosa
T4 Tumor invades adjacent structures Perforates serosa; adjacent
structures
Table 2 | Comparison of T stage of appendiceal NENs between ENETS
and UICC.
ENETS UICC
T1 Tumor ≤1 cm invading submucosa
and muscularis propria
≤2 cm (T1a, ≤1 cm; T1b,
>1–2 cm)
T2 Tumor ≤2 cm invading submucosa,
muscularis propria and/or minimally
(up to 3mm) invading
subserosa/mesoappendix
>2–4 cm; cecum
T3 Tumor >2 cm and/or extensive
(more than 3mm) invasion of
subserosa/mesoappendix
>4 cm; ileum
T4 Tumor invades peritoneum/other
organs
Perforates peritoneum;
other organs or structures
IMMUNOHISTOCHEMISTRY OF NEUROENDOCRINE
MARKERS
The histological diagnosis of NENs is generally confirmed by
immunohistochemical demonstration of neuroendocrine mark-
ers (Hirabayashi et al., 2006; Kajiwara et al., 2009; Yazawa et al.,
2011). Several general neuroendocrine markers are known: chro-
mogranin, synaptophysin, protein cell product 9.5, neural cell
adhesion molecule (NCAM/CD56), neuron-specific enolase, and
Leu 7. Chromogranin A and synaptophysin are the most com-
mon markers to confirm the endocrine nature of the neoplastic
cells. Chromogranin A is one of the acidic proteins belong-
ing to the chromogranin/secretogranin family and is present in
the secretory granules of neuroendocrine cells (Lloyd, 2003).
Chromogranin A is an important marker for NENs; however,
its expression is focal or negative in NENs with few secretory
granules (Wilson and Lloyd, 1984; Lloyd, 2003). Expression of
chromogranin A in NETs tends to be strong and diffusely dis-
tributed; NECs, in contrast, express chromogranin A weakly or
not at all (Rindi et al., 2000b, 2006). In addition, chromogranin
A expression tends to be weaker in hindgut NENs (Al-Khafaji
et al., 1998). Hindgut NENs are often positive for chromogranin
B; therefore, using antibodies against chromogranin B or a com-
bination of staining for chromogranin A and B may be useful
for the diagnosis for hindgut NENs (Lloyd, 2003). Synaptophysin
is a component of the presynaptic vesicle membrane and is
FIGURE 3 | “Crush”artifacts of esophageal small cell carcinoma (upper
right) [hematoxylinand eosin (H and E) stain].
widely distributed in neuroendocrine cells and neurons (Gould
et al., 1986; Lloyd, 2003). Unlike chromogranin A, synaptophysin
is well preserved in high-grade NENs (Al-Khafaji et al., 1998;
Rindi et al., 2006).
BIOPSY AND CYTOLOGY OF GI-NENs
Obtaining GI-NEN tissues by endoscopic forceps biopsy is often
difficult due to their location in the deep mucosa and submu-
cosa. Even if biopsy is successful, the diagnosis of GI-NEN using
biopsy material is sometimes difficult due to small specimen size
or “crush” artifacts (Figure 3), which can lead to misdiagnosis
(Hoda and Hajdu, 1992; Brenner et al., 2004). Nevertheless, accu-
rate diagnosis from the initial biopsy is important because therapy
could differ depending on the diagnosis. Therefore, analysis using
neuroendocrine markers should be performed to rule out NENs
when tumors have strong crush artifacts in biopsy materials.
Fine-needle aspiration cytology is useful for diagnosing GI-NENs
because they are generally located in deep areas of the gastroin-
testinal tract (Benya et al., 1993; Acs et al., 2000; Tasso et al., 2012).
Brushing cytology for esophageal small-cell carcinoma also has
been reported (Chen, 2000).
Although biopsy and cytology are useful for the diagnosis of
NETs, the accuracy of diagnosis and the evaluation of grading
using this method can be limited by intratumoral heterogene-
ity (Couvelard et al., 2009; Yang et al., 2011). Couverlard et al.
studied the heterogeneity of the Ki-67 index by comparing two
random cores of liver metastasis from pancreatic NENs. They
found a good correlation of the Ki-67 index (intraclass corre-
lation coefficient, 0.63) between cores (Couvelard et al., 2009).
In contrast, Yang et al. reported that about half of the NENs
metastasizing to the liver show intratumoral heterogeneity for
Ki-67 grading (G1 vs. G2) on whole-slide subsections (Yang
et al., 2011). Furthermore, if biopsy or cytology samples are
small, they might not contain adequate numbers of tumor cells
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for the determination of the Ki-67 index and mitotic count.
Another problem is the distribution of neuroendocrine compo-
nents in MANEC or NENs coexisting with other tumors. Biopsy
or cytological materials ofMANECor NENs coexisting with other
tumors may not contain neuroendocrine components. This sit-
uation can lead to misdiagnosis or difficulty in the diagnosis of
NENs on biopsy and cytology. Therefore, in some cases, multi-
ple biopsies or cytological analyses may be needed for accurate
diagnosis.
GENETIC ANDMOLECULAR ASPECTS OF GI-NENs
Alterations of MEN1 gene (11q13) cause multiple endocrine neo-
plasia type 1 (MEN1) syndrome. Several sporadic GI-NENs show
alterations of MEN1 gene. The incidence of loss of heterozygosity
(LOH) of the MEN1gene is 39% of GI-NENs (Rindi and Bordi,
2005). The mutation and promoter methylation of the MEN1
gene are 27% (Rindi and Bordi, 2005) and 23% (Arnold et al.,
2007), respectively.
LOH has been occasionally found in the following tumor sup-
pressor genes or chromosomes encoding tumor suppressor genes:
chromosome 17p encoding the TP53 gene, chromosome 3p
encoding the RAS association domain family 1A (RASSF1A) gene,
chromosome 9p encoding p16-INK4a and p14-ARF genes, and
chromosome 18q encoding DCC, DPC4/SMAD4, and SMAD2
genes (Terris et al., 1998; Zhao et al., 2000; Lollgen et al., 2001;
Chan et al., 2003; Pizzi et al., 2003; Stancu et al., 2003; Pizzi
et al., 2005; Rindi and Bordi, 2005). The incidence of TP53 muta-
tion is 4–44% (Ramnani et al., 1999; Rindi and Bordi, 2005).
No mutation of the p16-INK4a gene or smad4/DPC4 gene has
been reported in GI-NENs (Lollgen et al., 2001; Chan et al., 2003;
Stancu et al., 2003).
GI-NENs show frequent methylation of RASSF1A, p14-ARF,
retinoic acid receptor beta 2 (RARβ), O6-methyl-guanine
methyltransferase (MGMT), cyclooxygenase 2 (COX-2), throm-
bospondin 1 (THBS1), estrogen receptor (ER), and hyperme-
thylated in cancer 1 (HIC-1) (Chan et al., 2003; Liu et al.,
2005; Pizzi et al., 2005; Zhang et al., 2006; Arnold et al., 2007).
p16-INK4 methylation is present in 33% of GI-NENs accord-
ing to the results of several studies (Serrano et al., 2000; Chan
et al., 2003; Liu et al., 2005). However, the results of a large series
by Arnold et al. show no methylation of p16-INK4 in GI-NENs
(Arnold et al., 2007). The methylation of RASSF1A gene is asso-
ciated with distant or lymph node metastasis (Liu et al., 2005;
Zhang et al., 2006).
Several authors have studied the alteration of tumor oncogenes
such as HER2/neu, Ras family, and BRAF in GI-NENs. Azzoni
et al. reported that 24 cases of ileal NENs showed no amplifica-
tion of HER2/neu (Azzoni et al., 2011). In contrast, Evers et al.
reported that 3 out of 9 cases of GI-NENs showed HER2/neu
amplification, and they found a trend of increased HER-2/neu
copy number in the more aggressive GI-NENs (Evers et al., 1992).
The incidence of immunohistochemical expression of HER2/neu
has a broad range (Wang et al., 1997; Yamaguchi et al., 2007;
Arnason et al., 2011a; Azzoni et al., 2011). Mutation of the K-ras
and BRAF genesis rare in GI-NENs (Younes et al., 1997; Ramnani
et al., 1999; Stancu et al., 2003; Perren et al., 2004; Wang et al.,
2005; Van Eeden et al., 2007).
Alterations of Wnt signal-associated genes such as
beta-catenin and adenomatous polyposis coli (APC) have
been reported. Fujimori et al. reported mutations in exon 3 of
beta-catenin in 38% (27/72 cases) of GI-NENs and 1 mutation in
APC (1%, 1/72 case) (Fujimori et al., 2001). Furthermore, these
authors also revealed that 57 out of 72 cases (79%) involve cyto-
plasmic and/or nuclear accumulation of beta-catenin (Fujimori
et al., 2001). However, other authors reported no mutations in
the exon 3 beta-catenin or APC gene (Semba et al., 2000; Chan
et al., 2003; Stancu et al., 2003; Su et al., 2006), but the incidence
of cytoplasmic accumulation and/or nuclear translocation of
beta-catenin in GI-NENs was found to be 30–36% (Semba et al.,
2000; Su et al., 2006).
Microsatellite instability (MSI) causes several GI carcinomas.
The loss of expression of mismatch repair (MMR) proteins relates
to MSI. Most MMR proteins (MLH1, MSH2, MSH6, and PMS2)
are intact in small intestinal NENs (Kidd et al., 2005; Arnason
et al., 2011b) and in colorectal small cell carcinomas (hMLH1,
hMSH2, and hMSH6) (Stelow et al., 2006).
As for other molecular alterations, cDNA microarray analysis
of GI-NENs reveals that extracellular matrix protein 1 (ECM1),
vesicular monoaminemember1 (VMAT1), galectin 4 (LGALS4),
and RET proto-oncogene (RET) are highly up-regulated genes
(Duerr et al., 2008).
CHARACTERISTICS IN EACH SPECIFIC ORGAN
ESOPHAGUS
Most of the NENs arising from the esophagus are NECs, andNETs
are rare (Hoang et al., 2002). Esophageal NENs commonly occur
in themid to lower segments of the esophagus (Hoang et al., 2002;
Yun et al., 2007). Esophageal NETs appear to arise in two ways: as
an incidental finding in association with Barrett esophagus and
adenocarcinoma or as a single large polypoid or nodular tumor
(Hoang et al., 2002). Upon immunohistochemistry, esophageal
NETs are observed to strongly express chromogranin and synap-
tophysin, and some additionally express serotonin, glucagon, or
pancreatic polypeptide (Hoang et al., 2002). Esophageal small-
cell carcinoma has similar histological features to lung small-cell
carcinoma (Yun et al., 2007). The majority of pulmonary small-
cell carcinomas express thyroid transcription factor-1 (TTF-1)
(Ordonez, 2000). Similarly, esophageal small-cell carcinomas also
often express TTF-1 (33–71%) (Yamamoto et al., 2003; Yun
et al., 2007). Combined tumors of NEC and squamous cell car-
cinoma have been reported (Figure 4) (Yamamoto et al., 2003).
Esophageal NECs coexisting with Barrett mucosa or Barrett’s
esophageal adenocarcinoma have been also reported, as have
NETs (Bibeau et al., 2008). Some cases of esophageal NENs
show endocrine cell hyperplasia in the Barrett mucosa, as well
as invasive adenocarcinoma (Hoang et al., 2002). The presence
of endocrine cell hyperplasia in Barrett mucosa and adenocar-
cinomas supports the hypothesis that esophageal NENs, Barrett
mucosa, and adenocarcinomas arise from a common stem cell
(Hoang et al., 2002).
STOMACH
Gastric NETs are classified into three types (Rindi et al., 1993;
Kloppel et al., 2004, 2007; Scherubl et al., 2010). Type-1 NET is
Frontiers in Oncology | Gastrointestinal Cancers January 2013 | Volume 3 | Article 2 | 4
Hirabayashi et al. Review of GI-NENs
the most common (70–80%). Type-1 NET is related to chronic
atrophic gastritis (Rindi et al., 1993; Scherubl et al., 2010) and
occur in the corpus and/or fundus of the stomach as multifocal,
small, polypoid tumors (<10mm) (Rindi et al., 1993; Scherubl
et al., 2010). Type-2 NETs account for 5–6% of gastric NETs and
most commonly arise in the corpus and/or fundus of the stom-
ach as multiple mucosal or submucosal small tumors (<10mm)
(Rindi et al., 1993; Scherubl et al., 2010). Type-2 NET is involved
in MEN-1 and Zollinger–Ellison syndrome (ZES) (Rindi et al.,
1993; Scherubl et al., 2010). Type-3 NETs account for 14–25%
FIGURE 4 | Combined tumors of neuroendocrine carcinoma (NEC) (left)
and squamous cell carcinoma (right) (H and E stain).
of gastric NETs and occur in any part of the stomach as solitary
polypoid tumors (Rindi et al., 1993; Scherubl et al., 2010). These
tumors are larger than Type-1 and Type-2 NETs. In one-third of
the cases, the tumor was already larger than 2 cm at the time of
diagnosis (Kloppel et al., 2004).
Type-1 and Type-2 NETs are associated with
enterochromaffin-like-cell (ECL-cell) hyperplasia and hyper-
gastrinemia. In contrast, Type-3 NETs are not associated with
these conditions (Scherubl et al., 2010). Type-1, 2, and most
Type-3 NETs are considered to originate from histamine-
producing ECL-cells which immunohistochemically express
vesicular monoamine transporter 2 (Rindi et al., 2000a;
Kloppel et al., 2004, 2007; Scherubl et al., 2010). Histologically,
Type-1 and Type-2 NETs show a trabecular or nodular pat-
tern (Figures 5A–D). The Ki-67 index is usually less than 2%
(Scherubl et al., 2010). Most Type-3 NETs are more aggressive
than Type-1 and Type-2 NETs; they are arranged in a solid,
trabecular pattern and occasionally have a high proliferation
rate (Kloppel et al., 2007; Scherubl et al., 2010). Type-3 NETs
often invade deeply, display lymphatic and vascular inva-
sion, and are associated with local and/or distant metastases
(Rindi et al., 1999).
NECs present as solitary, large, ulcerated tumors arising in any
part of the stomach (Kloppel et al., 2007; Scherubl et al., 2010).
Histological features of gastric NECs are similar to those of small-
cell or large-cell NETs of the lung (Scherubl et al., 2010).
DUODENUMAND PROXIMAL JEJUNUM
The most common non-MEN1-associated duodenal NET
is gastrin-producing NET (46%), followed by somatostatin-
producing NET (18%) (Kloppel et al., 2007; Garbrecht
FIGURE 5 | Type-1 neuroendocrine neoplasm (NEN) of the stomach.
Tumor cells proliferate in a trabecular fashion in the submucosa.
Enterochromaffin-like-cell (ECL-cell) hyperplasia is scattered in the mucosa
(H and E stain, A: low power view, B: high power view). Synaptophysin is
positive for tumor and ECL-cell hyperplasia (C: low power view, D: high power
view).
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et al., 2008). MEN1 syndrome is associated with 25–33%
of duodenal gastrin-producing NETs (Kloppel et al., 2007).
Of the gastrin-producing NETs, 47% show functional activ-
ity, which causes ZES (Kloppel et al., 2007; Garbrecht et al.,
2008). A gastrin-producing NET presents as a small poly-
poid tumor within the submucosa and commonly occurs in
the first part of the duodenum (Kloppel et al., 2004, 2007).
MEN1-associated gastrin-producing NETs are multiple and tiny
(sometimes less than 1mm in diameter) (Anlauf et al., 2005;
Kloppel et al., 2007). Histologically, gastrin-producing NETs
show trabecular and pseudoglandular patterns with immunohis-
tochemical gastrin expression (Figures 6A–D). The most com-
mon region in which somatostatin-producing NETs arise is
the papilla of Vater (Figure 7A) (Burke et al., 1997; Garbrecht
et al., 2008). About 43% of somatostatin-producing NETs and
14% of non-MEN1-associated somatostatin-producing NETs are
FIGURE 6 | Gastrin-producing NETs of the duodenum. Tumor shows trabecular and pseudoglandular patterns (H and E stain, A: low power view, B: high
power view) with immunohistochemical gastrin expression (C). Gastrin-producing NETs metastasize to the lymph node (D).
FIGURE 7 | Somatostatin-producing NETs arising from the papilla of
Vater. Macroscopic findings show the solid, polypoid mass in the papilla of
Vater (A). The tumor is arranged in a trabecular pattern with pseudoglandular
structures (H and E stain, B: low power view, C: high power view).
Psammoma bodies are present (C). Immunohistochemically, the tumor cells
are positive for somatostatin (D).
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associated with neurofibromatosis type 1 (Soga and Yakuwa,
1999; Garbrecht et al., 2008). Although somatostatin-producing
NETs show immunohistochemical positivity for somatostatin
(Figure 7D), somatostatin syndrome does not usually develop
(Garbrecht et al., 2008). Somatostatin-producing NETs are
arranged in a trabecular pattern with pseudoglandular struc-
tures (Figures 7B and C). Psammoma bodies are occasionally
present (Figure 7C) (Soga and Yakuwa, 1999; Garbrecht et al.,
2008). MEN1-associated somatostatin-producing NETs accom-
pany somatostatin cell hyperplasia of the non-neoplastic mucosa
(Garbrecht et al., 2008). Duodenal NECs most commonly arise
in the papilla of Vater (Zamboni et al., 1990; Nassar et al.,
2005; Kloppel et al., 2007). Nassar et al. reported 14 cases of
ampullary NECs comprising 8 cases (57%) of large-cell neuroen-
docrine carcinoma and 6 cases (43%) of small-cell carcinoma
(Nassar et al., 2005).
DISTAL JEJUNUM AND ILEUM
Most distal jejunal and ileal NETs are serotonin-producing
EC-cell NETs (Levy and Sobin, 2007). Carcinoid syndrome
usually occurs due to the hormonal effects of serotonin when
the tumor metastasizes to the liver (Kloppel et al., 2007; Levy
and Sobin, 2007). Macroscopically, most NETs of the distal
jejunum and ileum occur at the terminal ileum either as sin-
gle small sessile nodules usually measuring between 1 and
2 cm or as multiple tumors (Burke et al., 1997; Yantiss et al.,
2003; Kloppel et al., 2007). Histologically, EC-cell NETs pro-
liferate in an insular growth pattern, with solid to cribriform
tumor structures. Glandular-like structures or palisading of
the peripheral cell layers are occasionally seen (Kloppel et al.,
2004, 2007; Levy and Sobin, 2007). S-100 protein positivity
has been reported in sustentacular-like cells in 7% of tumors
(Burke et al., 1997).
APPENDIX
The most common site in which appendiceal NETs arise is the tip
of the appendix (Carr and Sobin, 2004). EC-cell NETs account for
a substantial portion of the appendiceal NETs (Carr and Sobin,
2004). The histological features of appendiceal EC-cell NETs are
comparable to those of the ileal EC-cell NETs (Figures 8A–C)
(Kloppel et al., 2004). S100-positive sustentacular cells have also
been identified (Figure 8D) (Carr and Sobin, 2004). Two spe-
cial types of appendiceal NENs are tubular carcinoid (TC) and
goblet cell carcinoid (GCC). According to the current WHO clas-
sification, TC is classified as a NET, and GCC, as a MANEC
(Bosman et al., 2010). TC forms discrete tubules and short lines
of cells within an abundant stroma, and some contain mucus in
the lumen (Carr and Sobin, 2004). Misdiagnosis TC as metastatic
adenocarcinoma is a well-known pitfall about NET (Bosman
et al., 2010). GCC is a unique histologic variation of NEN,
showing both neuroendocrine and ductal differentiations (Roy
and Chetty, 2010; Yong et al., 2010). GCC commonly prolif-
erates in the lamina propria or submucosa at the tip of the
appendix and macroscopically presents as a solid, hard, gray-
ish ill-demarcated tumor (Roy and Chetty, 2010; Yong et al.,
2010). Tumor cells of GCC possess intracytoplasmic mucus,
which is similar to goblet cells or signet-ring cells, with small,
compressed nuclei (Figure 9A) (Yong et al., 2010). Tumors pro-
liferate with tight solid nests or tubules that have small lumina
and invade the muscular layer, serosa, and mesoappendiceal
tissues (Yong et al., 2010). GCCs are more aggressive than con-
ventional NETs but less than adenocarcinomas of the appendix
(Bosman et al., 2010). The Ki-67 index is >2% in 41% (7/17
cases) of GCC (Alsaad et al., 2007). Immunohistochemically,
GCCs show strong carcinoembryonic antigen and cytokeratin
positivity and are inconsistently positive for neuroendocrine
markers such as chromogranin A and synaptophysin (Figure 9B)
FIGURE 8 | EC-cell NETs of the appendix. The tumor proliferates in an insular growth pattern, with solid to cribriform tumor structures (H and E stain, A). The
tumor cells are positive for synaptophysin (B) and serotonin (C). S-100 protein positivity is observed in sustentacular-like cells (D).
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FIGURE 9 | Goblet cell carcinoid of the appendix. (A) Tumor cells of
goblet cell carcinomas possess intracytoplasmic mucus with small,
compressed nuclei. (B) Tumor cells are focally positive for synaptophysin.
(Alsaad et al., 2007; Yong et al., 2010). GCCs have been reported
to show CK20 positivity in 100% of cases (17/17 cases) and
CK7 positivity in 71% (12/17 cases), whereas conventional NETs
showed CK20 positivity in 16% of cases (4/25 cases) and CK7
negativity in all cases (Alsaad et al., 2007). Tang et al. showed
that GCCs display a spectrum of histologic features and pos-
sess the potential to transform into adenocarcinomas, with either
the signet-ring cell phenotype or the poorly differentiated ade-
nocarcinoma phenotype. The adenocarcinoma ex GCC showed
the worse prognosis (stage IV-matched 5-year survival: typical
GCC, 100%; signet-ring cell type, 38%; poorly differentiated
adenocarcinoma type, 0%) (Tang et al., 2008).
COLON AND RECTUM
Rectal NETs are more common than colonic NETs (Kloppel et al.,
2007). Macroscopically, rectal NETs present as solitary sessile
or semi-pedunculated tumors with intact overlying epithelium
(Shim et al., 2004) (Figure 1). Larger neoplasms can be ulcerated
(Shim et al., 2004). Histologically, rectal NETs show a charac-
teristic trabecular pattern (Figures 10A and B) (Kloppel et al.,
2007). Immunohistochemically, rectal NETs are usually positive
for prostatic acid phosphatase and synaptophysin and negative
for chromogranin A (Figures 10C andD) (Federspiel et al., 1990;
Kloppel et al., 2007). Themajority of colonic NETs are detected in
the cecum (Soga, 1998). Histologically, colonic NETs proliferate
with a nodular, trabecular, or mixed pattern (Soga, 1998; Kloppel
et al., 2007). Immunohistochemically, NETs of the cecal region are
positive for serotonin (Kloppel et al., 2007). NECs are more com-
mon in the colon, especially the right colon, than in the rectum
(Kloppel et al., 2007; Bosman et al., 2010). Large-cell carcinoma is
themost common colorectal NEC (51%, 19/37 cases), followed by
small-cell carcinoma (24%, 9/37 cases) and mixed carcinoma of
FIGURE 10 | Microscopic findings of rectal NET. Rectal NET shows a trabecular proliferating pattern (A: low power view, B: high power view).
Immunohistochemically, tumor cells of rectal NET are positive for synaptophysin (C) but negative for chromogranin A (D).
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small cell carcinoma and large call carcinoma (24%, 9/37) (Shia
et al., 2008). Colonic NECs are frequently associated with an over-
lying adenoma or adenocarcinoma but are not associated with
NETs (Shia et al., 2008).
CONCLUSIONS
Although GI-NENs have common histological features, micro-
scopic and immunophenotypic features have to be considered in
the different anatomical sites.
The recent WHO classification and ENETS grading systems
are based on the Ki-67 index and mitotic count in histolog-
ical material. Intratumoral heterogeneity, especially in biopsy
and cytological materials, limits the diagnostic accuracy of the
grading system. For accurate grading and pathological diag-
nosis, it is important to carefully evaluate hot spots for the
Ki-67 index, identify areas of highest mitotic density for mitotic
count, and recognize the characteristic histological features of
GI-NENs.
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